Deepak Perumal
Overview
Explore the profile of Deepak Perumal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
543
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oriol A, Hajek R, Spicka I, Sandhu I, Cohen Y, Gatt M, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jun;
24(10):703-714.
PMID: 38849283
Background: Preclinical studies suggest that combining nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, with pomalidomide/dexamethasone (Pd) with or without elotuzumab, an antisignaling lymphocytic activation molecule F7 monoclonal antibody, may...
2.
Fernandez N, Perumal D, Rahman A, Kim-Schulze S, Yesil J, Auclair D, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Aug;
22(11):853-862.
PMID: 35945129
Background: Multiple myeloma (MM) is a malignancy of plasma cells that arises from premalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) and often progresses through an asymptomatic Smoldering (SMM) phase. Understanding...
3.
Ma M, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, et al.
Haematologica
. 2021 Apr;
107(3):690-701.
PMID: 33792219
B-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL, such as diffuse large B-cell lymphoma, have been comprehensively...
4.
Mei A, Tung K, Han J, Perumal D, Lagana A, Keats J, et al.
Oncotarget
. 2020 Mar;
11(7):727-739.
PMID: 32133047
The type I Melanoma Antigen Gene (MAGE) A3 is a functional target associated with survival and proliferation in multiple myeloma (MM). To investigate the mechanisms of these oncogenic functions, we...
5.
Perumal D, Imai N, Lagana A, Finnigan J, Melnekoff D, Leshchenko V, et al.
Clin Cancer Res
. 2019 Dec;
26(2):450-464.
PMID: 31857430
Purpose: Somatic mutations in cancer cells can give rise to novel protein sequences that can be presented by antigen-presenting cells as neoantigens to the host immune system. Tumor neoantigens represent...
6.
Lagana A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, et al.
JCO Precis Oncol
. 2019 Feb;
2018.
PMID: 30706044
Purpose: Multiple myeloma (MM) is a malignancy of plasma cells, with a median survival of 6 years. Despite recent therapeutic advancements, relapse remains mostly inevitable, and the disease is fatal...
7.
Kuo P, Jatiani S, Rahman A, Edwards D, Jiang Z, Ahr K, et al.
Blood
. 2018 Apr;
131(20):2247-2255.
PMID: 29615403
Mantle cell lymphoma (MCL) is characterized by increased B-cell receptor (BCR) signaling, and BTK inhibition is an effective therapeutic intervention in MCL patients. The mechanisms leading to increased BCR signaling...
8.
Chari A, Cho H, Dhadwal A, Morgan G, La L, Zarychta K, et al.
Blood Adv
. 2018 Jan;
1(19):1575-1583.
PMID: 29296798
Phase 3 studies combining histone deacetylase inhibitors with bortezomib were hampered by gastrointestinal (GI) intolerance, which was not observed when combined with immunomodulatory drugs. This study is a single-center phase...
9.
Kotini A, Chang C, Chow A, Yuan H, Ho T, Wang T, et al.
Cell Stem Cell
. 2017 Feb;
20(3):315-328.e7.
PMID: 28215825
Myeloid malignancy is increasingly viewed as a disease spectrum, comprising hematopoietic disorders that extend across a phenotypic continuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) and acute myeloid leukemia...
10.
Perumal D, Kuo P, Leshchenko V, Jiang Z, Divakar S, Cho H, et al.
Cancer Res
. 2016 Feb;
76(5):1225-36.
PMID: 26873845
Multiple myeloma is a fatal plasma cell neoplasm accounting for over 10,000 deaths in the United States each year. Despite new therapies, multiple myeloma remains incurable, and patients ultimately develop...